Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1.
The vaccine potential of a mutant herpes simplex virus (HSV) type 1, with a deletion in the glycoprotein H (gH) gene, was evaluated. The virus requires a gH-expressing cell line for multi-cycle growth but can complete a single cycle of infection in noncomplementing cells. Such viruses, termed DISC (disabled infectious single cycle) viruses, should be safe, yet still able to stimulate humoral and cell-mediated responses against a broad range of virus antigens in vaccinated hosts. Prophylactic vaccination of guinea pigs with DISC HSV-1, by ear scarification or direct infection of the vaginal mucosa, afforded a high degree of protection against HSV-2-induced primary genital disease and reduced significantly the frequency of subsequent disease recurrence. There was also a trend toward reduced recurrence following therapeutic vaccination of animals already infected with HSV-2. DISC HSV vaccination, therefore, offers an effective route for control of HSV disease.
Cantab Pharmaceuticals Research Ltd., Cambridge, United Kingdom.
C S
CS
McLean
M
M
Erturk
R
R
Jennings
D N
DN
Challanain
A C
AC
Minson
I
I
Duncan
M E
ME
Boursnell
S C
SC
Inglis
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D006168:Guinea Pigs; D006558:Herpes Genitalis / Q000517:prevention & control*; D018259:Herpesvirus 1, Human / Q000235:genetics / Q000276:immunology*; D009154:Mutation; D012008:Recurrence; D014611:Vaccination; D014765:Viral Vaccines / Q000276:immunology*; D014779:Virus Replication
D000914:Antibodies, Viral; D014765:Viral Vaccines